Related Experiment Video
Updated: May 1, 2026
Author Spotlight: Revolutionizing Pancreatic Disease Understanding Through Advanced Intravital Imaging
Published on: October 6, 2023
Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134
Yassar M Hashim1, Dirk Spitzer2, Suwanna Vangveravong1
1Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States.
Abstract:
Pancreatic adenocarcinoma is highly resistant to conventional therapeutics and has been shown to evade apoptosis by deregulation of the X-linked and cellular inhibitors of apoptosis proteins (XIAP and cIAP). Second mitochondria-derived activator of caspases (Smac) induces and amplifies cell death by reversing the anti-apoptotic activity of IAPs. Thus, Smac-derived peptide analogues (peptidomimetics) have been developed and shown to represent promising cancer therapeutics. Sigma-2 receptors are overexpressed in many proliferating tumor cells including pancreatic cancer. Selected ligands to this receptor are rapidly internalized by cancer cells. These characteristics have made the sigma-2 receptor an attractive target for drug delivery because selective delivery to cancer cells has the potential to increase therapeutic efficacy while minimizing toxicity to normal tissues. Here, we describe the initial characterization of SW IV-134, a chemically linked drug conjugate between the sigma-2 ligand SW43 and the Smac mimetic SW IV-52 as a novel treatment option for pancreatic adenocarcinoma. The tumor killing characteristics of our dual-domain therapeutic SW IV-134 was far greater than either component in isolation or in an equimolar mix and suggests enhanced cellular delivery when chemically linked to the sigma-2 ligand. One of the key findings was that SW IV-134 retained target selectivity of the Smac cargo with the involvement of the NF-κB/TNFα signaling pathway. Importantly, SW IV-134 slowed tumor growth and improved survival in murine models of pancreatic cancer. Our data support further study of this novel therapeutic and this drug delivery strategy because it may eventually benefit patients with pancreatic cancer.
Insights
A novel dual-domain therapeutic, SW IV-134, combines a sigma-2 receptor ligand with a Smac mimetic to target pancreatic cancer. This conjugate effectively kills tumor cells, slows growth, and improves survival in preclinical models.
Area of Science:
- Oncology
- Drug Discovery
- Molecular Biology
Background:
- Pancreatic adenocarcinoma exhibits resistance to conventional therapies, partly due to the deregulation of apoptosis inhibitors like XIAP and cIAP.
- Second mitochondria-derived activator of caspases (Smac) mimetics reverse anti-apoptotic activity, offering therapeutic potential.
- Sigma-2 receptors are overexpressed in pancreatic tumors and can be targeted for selective drug delivery.
Purpose of the Study:
- To characterize SW IV-134, a novel drug conjugate linking a sigma-2 receptor ligand (SW43) with a Smac mimetic (SW IV-52).
- To evaluate SW IV-134 as a potential therapeutic agent for pancreatic adenocarcinoma.
- To assess the efficacy and mechanism of action of this dual-domain therapeutic.
Main Methods:
- Chemical synthesis of the dual-domain conjugate SW IV-134.
- In vitro characterization of tumor cell killing properties.
- Assessment of target selectivity and signaling pathway involvement (NF-κB/TNFα).
- In vivo evaluation in murine models of pancreatic cancer to assess tumor growth inhibition and survival.
Main Results:
- SW IV-134 demonstrated significantly enhanced tumor killing compared to individual components or an equimolar mix.
- The conjugate's efficacy is attributed to enhanced cellular delivery via the sigma-2 receptor ligand.
- SW IV-134 retained Smac mimetic activity, involving the NF-κB/TNFα signaling pathway.
- In vivo studies showed SW IV-134 slowed tumor growth and improved survival in pancreatic cancer models.
Conclusions:
- SW IV-134 represents a promising novel therapeutic strategy for pancreatic adenocarcinoma.
- The drug delivery approach utilizing sigma-2 receptor targeting enhances therapeutic efficacy.
- Further investigation of SW IV-134 and this targeted delivery strategy is warranted for potential clinical benefit.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
05:49Generation of an Orthotopic Xenograft of Pancreatic Cancer Cells by Ultrasound-Guided Injection
Published on: November 1, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...